Trials / Completed
CompletedNCT00266006
Factor VIIa in Acute Intracerebral Haemorrhage
Safety of Eptacog Alfa (Activated) (Genetical Recombination) on Adverse Events and Serious Adverse Events in Patients With Acute Intracerebral Haemorrhage.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This trial is conducted in Japan. The purpose of this trial is to evaluate the safety and preliminary efficacy of Activated Recombinant Factor VII (NN-007) in patients with acute intracerebral haemorrhage.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | eptacog alfa (activated) |
Timeline
- Start date
- 2006-01-01
- Primary completion
- 2007-04-01
- Completion
- 2007-04-01
- First posted
- 2005-12-15
- Last updated
- 2016-11-18
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00266006. Inclusion in this directory is not an endorsement.